A Comparative Effectiveness Study of Lorazepam or IVIg Versus no Treatment for Down Syndrome Regression Disorder

20260 citationsJournal Articlegold Open Access

Authors

Jonathan D. Santoro · University of Southern California

Saba Jafarpour · University of Southern California

Panteha Hayati Rezvan · Children's Hospital of Los Angeles

Mellad Khoshnood · Santa Barbara Cottage Hospital

Benjamin N. Vogel · Children's Hospital of Los Angeles

Lina Nguyen · Children's Hospital of Los Angeles

Lilia Kazerooni

Abstract

At the endpoint of 24 weeks, both IVIg and lorazepam were superior to no treatment for DSRD but IVIg was superior to lorazepam for all five outcomes. Between 12 and 24 weeks of treatment, IVIg showed greater improvement in all outcomes than did lorazepam, suggesting that at least a 24-week treatment course is necessary for maximum IVIg benefit.

Topics & Keywords

Down syndrome and intellectual disability research Diabetes Management and Research Personality Disorders and Psychopathology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology and Therapy

DOI: 10.1007/s40120-026-00906-2

Field-Weighted Citation Impact: 0.00